Fulminant Hepatic Failure due to Nilutamide Hepatotoxicity
- 68 Downloads
We report the case of a 76-year-old man who developed fulminant hepatic failure after treatment with the anti-androgen nilutamide (Nilandron). Both reversible and fatal liver toxicity have been described in patients treated with flutamide, an analogue of nilutamide, although this has been less commonly described with nilutamide itself . Our patient was prescribed nilutamide as part of combined androgen blockade. The patient’s liver biopsy was consistent with a drug-induced hepatitis. The patient developed fulminant hepatic failure which appears attributable to the use of nilutamide as viral hepatitis infection, other infections, toxins, and autoimmune causes were excluded.
A 76-year-old African American man with prostate cancer was transferred to our facility from a community hospital. The patient was initially diagnosed with prostate cancer 5 years ago, treated with a radical prostatectomy, and followed up by his urologist. The patient had been found to...
KeywordsNimesulide Hepatotoxicity Flutamide Fulminant Hepatic Failure Bicalutamide
- 6.Pescator P, Hammel P, Durand F, Berthau P, Bernuau J, Huc D et al (1993) Fatal fulminant hepatitis induced by nilutamide (Anondron). Gastroenterol Clin Biol 17(6–7):499–501Google Scholar
- 12.Fau D, Berson A, Eugene D, Fromenty B, Fisch C, Pessayre D (1992) Mechanism for the hepatotoxicity of the antiandrogen, nilutamide. Evidence suggesting that redox cycling of this nitroaromatic drug leads to oxidative stress in isolated hepatocytes. J Pharmacol Exp Ther 263(1):69–77PubMedGoogle Scholar
- 14.Lupron®. Product monograph (December 2007). TAP pharmaceuticals, Lake Forest, IL 60045, USAGoogle Scholar
- 17.Boccardo F, Pace M, Rubagotti A, Guarneri D, Decensi A, Oneto F et al (1993) Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group. Eur J Cancer 29A(8):1088–1093. doi: 10.1016/S0959-8049(05)80293-X PubMedCrossRefGoogle Scholar